KRAS oncogenes have been identified in a quarter of all human tumors and appear with high prevalence in some of the most lethal types of cancer such as pancreatic ductal adenocarcinoma (PDAC, 95%), colorectal carcinoma (CRC, 50%), and lung adenocarcinoma (LUAD, 30%). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.